This Article Full Text Full Text (PDF) All Versions of this Article: 90/9/5333    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dagogo-Jack, S. Articles by Umamaheswaran, I. Search for Related Content PubMed PubMed Citation Articles by Dagogo-Jack, S. Articles by Umamaheswaran, I. Related Collections Adrenal and Hypertension Metabolism Obesity

Inhibition of Cortisol Biosynthesis Decreases Circulating Leptin Levels in Obese Humans

Department of Medicine and General Clinical Research Center (S.D.-J.), University of Tennessee Health Science Center, Memphis, Tennessee 38163; and Division of Endocrinology, Diabetes and Metabolism (G.T., I.U.), Washington University School of Medicine, St. Louis, Missouri 63110

Address all correspondence and requests for reprints to: Samuel Dagogo-Jack, M.D., University of Tennessee College of Medicine, 956 Court Avenue, Suite D334, Memphis, Tennessee 38163. E-mail: sdj{at}utmem.edu.

Abstract

Context: Glucocorticoids increase both appetite and leptin secretion; the hyperleptinemic effect might be a counterregulatory response to the orexigenic effect of glucocorticoids. However, the effect of glucocorticoid inhibition on leptin production has not been reported.

Objective: We tested the hypothesis that if glucocorticoid-induced hyperleptinemia plays a physiological role, then inhibition of endogenous cortisol biosynthesis should decrease leptin secretion.

Design: A randomized, placebo-controlled, cross-over study design was used.

Setting: The study was carried out at a General Clinical Research Center.

Participants: Eight obese subjects (four men, four women; mean age, 30.4 ± 1.56 yr; mean body mass index, 42.0 ± 1.33 kg/m²) participated in the study.

Intervention: The subjects were treated with metyrapone (750 mg every 4 h) or placebo for 24 h during two overnight admissions, 2 wk apart. Blood sampling for measurement of cortisol, leptin glucose, insulin, and C-peptide was performed hourly for 6 h and every 2 h for 24 h.

Main Outcome Measure: The change in plasma leptin from baseline during metyrapone vs. placebo treatment was measured.

Results: Metyrapone treatment was associated with a significant decrease in plasma cortisol level; the cortisol nadir was 4.84 ± 1.22 µg/dl during placebo and 2.80 ± 0.65 µg/dl during metyrapone treatment (P = 0.009). Compared with placebo, metyrapone treatment was associated with a significant reduction in circulating leptin levels and marked attenuation of the nocturnal rise in plasma leptin (+28.45 ± 11.12% vs. +55.51 ± 5.42%; P = 0.01).

Conclusions: We conclude that metyrapone-induced inhibition of cortisol biosynthesis results in hypoleptinemia, which indicates that glucocorticoids may play an important role in the physiological regulation of leptin.

This article has been cited by other articles:

				K. K. Koh, S. M. Park, and M. J. Quon Leptin and Cardiovascular Disease: Response to Therapeutic Interventions Circulation, June 24, 2008; 117(25): 3238 - 3249. [Full Text] [PDF]

				B. Laferrere, C. Abraham, M. Awad, S. Jean-Baptiste, A. B. Hart, P. Garcia-Lorda, P. Kokkoris, and C. D. Russell Inhibiting Endogenous Cortisol Blunts the Meal-Entrained Rise in Serum Leptin J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2232 - 2238. [Abstract] [Full Text] [PDF]